Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Other Non Operating Income (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Other Non Operating Income for 7 consecutive years, with $1.4 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non Operating Income rose 256.49% year-over-year to $1.4 million; the TTM value through Mar 2026 reached $1.0 million, up 276.19%, while the annual FY2017 figure was $651212.0, 528.3% up from the prior year.
  • Other Non Operating Income hit $1.4 million in Q1 2026 for Crescent Biopharma, up from $1.3 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.4 million in Q1 2026 and bottomed at -$924000.0 in Q1 2025.